Geode Capital Management LLC Raises Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

Geode Capital Management LLC increased its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 0.9% in the third quarter, HoldingsChannel reports. The firm owned 912,202 shares of the company’s stock after buying an additional 8,133 shares during the quarter. Geode Capital Management LLC’s holdings in Shattuck Labs were worth $3,184,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in shares of Shattuck Labs by 8.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock worth $266,000 after purchasing an additional 5,397 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock valued at $183,000 after buying an additional 9,608 shares during the period. Atom Investors LP acquired a new stake in Shattuck Labs during the third quarter worth approximately $35,000. Readystate Asset Management LP purchased a new stake in Shattuck Labs in the 3rd quarter worth approximately $39,000. Finally, MetLife Investment Management LLC raised its holdings in Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after acquiring an additional 13,859 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Shattuck Labs presently has an average rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Down 5.2 %

STTK stock opened at $1.27 on Tuesday. The company has a market cap of $60.63 million, a PE ratio of -0.83 and a beta of 1.71. The stock has a 50-day moving average price of $1.18 and a two-hundred day moving average price of $2.50. Shattuck Labs, Inc. has a 12-month low of $0.94 and a 12-month high of $11.76.

Insider Activity

In other Shattuck Labs news, Director Redmile Group, Llc bought 133,371 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $1.25 per share, with a total value of $166,713.75. Following the purchase, the director now owns 5,539,724 shares in the company, valued at approximately $6,924,655. The trade was a 2.47 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.